abiraterone has been researched along with rucaparib in 1 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (rucaparib) | Trials (rucaparib) | Recent Studies (post-2010) (rucaparib) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 236 | 36 | 220 |
| Protein | Taxonomy | abiraterone (IC50) | rucaparib (IC50) |
|---|---|---|---|
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 0.0847 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.0418 | |
| Protein mono-ADP-ribosyltransferase PARP14 | Homo sapiens (human) | 8.8713 | |
| Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | 1.4333 | |
| Protein mono-ADP-ribosyltransferase PARP12 | Homo sapiens (human) | 6.6285 | |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 0.4523 | |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.0497 | |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 0.8354 | |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 0.4597 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abida, W; Bambury, RM; Bryce, AH; Chowdhury, S; Daugaard, G; Despain, D; Emmenegger, U; Fizazi, K; Gingerich, JR; Heidenreich, A; Heyes, CA; Krieger, L; Lindberg, H; Loehr, A; McDermott, R; Morris, D; Nolè, F; Ostler, P; Pintus, E; Piulats, JM; Reaume, MN; Redfern, C; Ryan, CJ; Sáez, MI; Sautois, B; Sridhar, SS; Staffurth, J; Watkins, SP | 1 |
1 trial(s) available for abiraterone and rucaparib
| Article | Year |
|---|---|
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Genes, BRCA1; Genes, BRCA2; Humans; Indoles; Male; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2023 |